XS0432810116

Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of NovartisNovartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis

Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis

After nearly seven years as a member of the Executive Committee of Novartis (ECN), Klaus Moosmayer will pursue his next…

19 hours ago
FDA approves Novartis radioligand therapy Pluvicto for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancerFDA approves Novartis radioligand therapy Pluvicto for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

FDA approves Novartis radioligand therapy Pluvicto for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to be used…

3 days ago
Novartis receives third FDA approval for oral Fabhalta (iptacopan) the first and only treatment approved in C3 glomerulopathy (C3G)Novartis receives third FDA approval for oral Fabhalta (iptacopan) the first and only treatment approved in C3 glomerulopathy (C3G)

Novartis receives third FDA approval for oral Fabhalta (iptacopan) the first and only treatment approved in C3 glomerulopathy (C3G)

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)…

2 weeks ago
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfrontNovartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is…

2 months ago
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024

Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024

Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +12% (cc1, +11% USD) with core operating income1 up…

2 months ago
Longer-term data for Novartis Scemblix reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CMLLonger-term data for Novartis Scemblix reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

Longer-term data for Novartis Scemblix reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2%…

4 months ago
New Phase IIIB data shows Novartis Fabhalta improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapyNew Phase IIIB data shows Novartis Fabhalta improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

New Phase IIIB data shows Novartis Fabhalta improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved the average hemoglobin (Hb) level versus baseline in adult patients…

4 months ago
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growthNovartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth

Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth

Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance upgraded to +6% CAGR 2023-2028 and +5% 2024-2029Strong momentum…

4 months ago